Conservative Management of NSTEMI
For NSTEMI patients managed conservatively (non-invasively), initiate dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (preferably ticagrelor), parenteral anticoagulation (preferably enoxaparin or fondaparinux over unfractionated heparin), continuous cardiac monitoring, and perform stress testing before discharge to identify patients requiring delayed angiography. 1, 2
Initial Medical Therapy
Antiplatelet Therapy
- Aspirin: Loading dose 150-300 mg orally (or 75-250 mg IV), followed by maintenance dose 75-100 mg daily indefinitely 1
- P2Y12 Inhibitor: Add to aspirin and continue for 12 months 1
Anticoagulation
- Preferred agents over unfractionated heparin: 2
- Unfractionated heparin: Continue for at least 48 hours if other agents unavailable 2
GP IIb/IIIa Inhibitors
- May be reasonable to add eptifibatide or tirofiban to antiplatelet and anticoagulant therapy in conservatively managed patients (Class IIb recommendation) 2
- Do NOT use abciximab in patients without planned PCI 2
Monitoring Requirements
- Continuous cardiac rhythm monitoring until NSTEMI diagnosis is established or ruled out 1
- Admit to monitored unit 1
- Duration of monitoring: 1
- Minimum 24 hours for low-risk patients
- Beyond 24 hours for patients at increased risk for arrhythmias
Risk Stratification and Stress Testing
Critical decision point: Patients without recurrent symptoms, heart failure, or serious arrhythmias must undergo stress testing before discharge 2
Stress Testing Protocol
- Perform non-invasive stress test (preferably with imaging) or coronary CT angiography if troponin normalizes and ECG remains stable 1, 2
- If stress test shows high risk: Proceed to diagnostic angiography 2
- If stress test shows low risk: Continue medical therapy and prepare for discharge 2
Indications to Convert to Invasive Strategy
Immediately proceed to angiography if any of the following develop: 2
- Recurrent ischemic symptoms despite medical therapy
- Heart failure
- Serious arrhythmias
- Hemodynamic instability
Discharge Planning for Low-Risk Patients
After negative stress testing: 2
- Continue aspirin indefinitely
- Continue P2Y12 inhibitor for at least 1 month (ideally up to 12 months)
- Discontinue parenteral anticoagulation
- Discontinue GP IIb/IIIa inhibitor if previously started
Evidence Quality and Nuances
Important caveats:
- Conservative strategy reduces procedure-related MI risk (nearly doubles with invasive approach) and bleeding complications 3, 4
- However, conservative strategy shows no mortality benefit compared to selective invasive approach at 6-12 months 3
- Conservative strategy is associated with higher rates of recurrent MI (RR 0.79 favoring invasive), refractory angina (RR 0.64 favoring invasive), and rehospitalization (RR 0.77 favoring invasive) 3
Special populations:
- Biomarker-negative patients: Conservative strategy is appropriate, particularly in women where invasive strategy shows no benefit 5
- Severe chronic kidney disease: Conservative or deferred invasive strategy preferred over early invasive approach 6
- Elderly patients (≥70 years): Recent meta-analyses show no mortality benefit from routine invasive strategy, though reduced recurrent MI and revascularization needs 7, 8, 9
Clinical reality: The 2020 ESC guidelines emphasize that truly conservative (purely medical) management is now rare, with most patients undergoing selective invasive strategy based on risk stratification 1. The evidence supports that a selective invasive approach guided by clinical risk is preferable to routine conservative management for most NSTEMI patients 3.